| 1 |
33144375 | In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix. | 2020 Nov 3 |
1 |
| 2 |
30753326 | Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients. | 2019 Sep 15 |
1 |
| 3 |
30958309 | Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. | 2019 |
2 |
| 4 |
26833162 | Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. | 2016 Apr |
2 |
| 5 |
27901085 | Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. | 2016 Nov 30 |
1 |
| 6 |
25397528 | Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels. | 2014 |
1 |
| 7 |
21949754 | Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. | 2011 |
1 |
| 8 |
20597164 | Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. | 2010 Jul 17 |
2 |